Break it Down: AdAlta moves into a higher realm of drug development with new advisory board

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on AdAlta (ASX:1AD) recruiting a team of world leaders in idiopathic pulmonary fibrosis to form a company clinical advisory board.

Therapeutic options for the debilitating inflammatory lung disease are limited and there’s currently no cure.

Tune in to get the latest.

While AdAlta is a Stockhead advertiser, it did not sponsor this content.